<p>启迪医疗系统（NYSE:INSP - 获取免费报告）在摩根大通的分析师发布的报告中，将其目标价格从 67.00 美元下调至 54.00 美元，Benzinga 报道。该券商目前对该股票给予 “中性” 评级。摩根大通的目标价格意味着该股票相较于之前收盘价有 11.94% 的潜在上涨空间。</p>
<ul>
<li>艾利 Lilly 股票上涨：GLP-1 Zepbound 目标睡眠呼吸暂停市场</li>
</ul>
<p>其他几家券商最近也对 INSP 发表了看法。派珀·桑德勒将启迪医疗系统的评级从 “增持” 下调至 “中性”，并在周二的研究报告中将其价格目标从 85.00 美元下调至 55.00 美元。扎克斯研究在 4 月 14 日的报告中将启迪医疗系统的评级从 “强力买入” 下调至 “持有”。加拿大皇家银行在周二的报告中将启迪医疗系统的价格目标从 56.00 美元下调至 45.00 美元，并对该股票设定了 “行业表现” 评级。摩根士丹利在 2 月 18 日的报告中对启迪医疗系统设定了 60.00 美元的目标价格。最后，Truist Financial 在周二的报告中将启迪医疗系统的股票价格目标从 64.00 美元下调至 50.00 美元，并对该股票设定了 “持有” 评级。四位分析师对该股票给予了买入评级，十五位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “持有”，共识目标价格为 85.00 美元。</p>
<p><strong>阅读我们最新的 INSP 股票分析</strong></p>
<h2>启迪医疗系统价格表现</h2>
<ul>
<li>启迪医疗上涨 15% 后突破，分析师称其为买入</li>
</ul>
<p>在周二的交易中，INSP 下跌 6.60 美元，报 48.24 美元。该股票的交易量为 4,487,559 股，而其平均交易量为 1,214,082 股。该公司的 50 日移动平均价格为 56.73 美元，200 日移动平均价格为 79.64 美元。该公司的市值为 13.9 亿美元，市盈率为 9.69，市盈增长比率为 2.92，贝塔值为 0.83。启迪医疗系统的年内最低价为 44.41 美元，年内最高价为 163.35 美元。</p>
<p>启迪医疗系统（NYSE:INSP - 获取免费报告）最后一次发布财报是在 5 月 4 日，周一。该公司报告每股收益为 0.10 美元，超出分析师共识预期的（0.28 美元）0.38 美元。启迪医疗系统的股本回报率为 10.96%，净利润率为 15.95%。该公司在该季度的收入为 2.0458 亿美元，而共识预期为 2.0004 亿美元。在去年同期，该公司每股收益为 0.10 美元。与去年同期相比，该公司的收入增长了 1.6%。启迪医疗系统将其 2026 财年的指导目标设定为 0.750-1.250 美元每股收益。作为一个整体，卖方分析师预测启迪医疗系统在当前财年将发布 1.82 美元的每股收益。</p>
<h2>启迪医疗系统的机构交易</h2>
<ul>
<li>小型股是否预示市场下跌？</li>
</ul>
<p>对该公司的对冲基金最近对其持仓进行了调整。CWM LLC 在第四季度将其在启迪医疗系统的股份增加了 216.1%。CWM LLC 现在拥有 354 股该公司的股票，价值 33,000 美元，此前在该期间又购买了 242 股。Havemeyer Place LP 在第四季度购买了启迪医疗系统的新股份，价值 39,000 美元。V Square Quantitative Management LLC 在第四季度购买了启迪医疗系统的新股份，价值 40,000 美元。Manning &amp; Napier Advisors LLC 在第三季度购买了启迪医疗系统的新股份，价值 32,000 美元。最后，Smartleaf Asset Management LLC 在第四季度将其在启迪医疗系统的股份增加了 84.0%。Smartleaf Asset Management LLC 现在拥有 449 股该公司的股票，价值 42,000 美元，此前在该期间又购买了 205 股。94.91% 的股票目前由机构投资者持有。</p>
<h2>启迪医疗系统新闻摘要</h2>
<p>以下是本周影响启迪医疗系统的主要新闻：</p>
<ul>
<li>积极情绪：第一季度业绩超出预期——启迪报告每股收益 0.10 美元，收入 2.046 亿美元，超出共识并显示出适度的同比增长；该公司还发布了季度材料和幻灯片。阅读更多。</li>
<li>积极情绪：一些公司仍持建设性态度——尽管目标被下调，Stifel 和 Mizuho 仍保持买入/跑赢大盘的立场（目标价格下调），表明一些分析师仍然看到低估值的上涨空间。阅读更多。</li>
<li>中性情绪：完整的财报电话会议记录和幻灯片可供详细查看——投资者可以查看管理层对编码、报销时机和 WISeR 计划影响的解释。阅读更多。</li>
<li>消极情绪：大幅下调 2026 财年指导——管理层现在预计每股收益为 0.75–1.25 美元，收入为 8.25 亿–8.75 亿美元，而市场预期接近每股收益 1.99 美元和收入约 9.61 亿美元，这一大幅下调的前景引发了投资者的担忧。阅读更多。</li>
<li>消极情绪：提到报销和 WISeR 计划的干扰——管理层表示，编码/报销时机和与 WISeR 相关的执行问题正在减少 2026 年的手术量，这是较弱指导的主要运营原因。阅读更多。</li>
<li>消极情绪：多位分析师下调目标价格和评级——几家券商下调了目标（Truist、富国银行、贝尔德）或转为中性/持有，指导失误后增加了卖压。阅读更多。</li>
</ul>
<h2>启迪医疗系统公司简介</h2>
<p>（获取免费报告）</p>
<p>启迪医疗系统公司是一家医疗科技公司，专注于用于治疗阻塞性睡眠呼吸暂停（OSA）的可植入神经刺激设备。该公司的旗舰产品启迪®系统，通过对舌下神经的定向刺激，在睡眠期间保持气道通畅，为对持续正压呼吸机（CPAP）设备不耐受或管理不当的患者提供了一种替代疗法。</p>
<p>启迪系统由一个可植入的脉冲发生器、一个监测呼吸模式的传感导线和一个激活舌下神经的刺激导线组成。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比启迪医疗系统更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 到启迪医疗系统吗？</h2>
<p>在你考虑启迪医疗系统之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而启迪医疗系统并不在名单上。</p>
<p>虽然启迪医疗系统目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

启迪医疗

摩根大通

标普健康医疗设备 ETF - SPDR

美国医药设备 ETF - iShares

医药突破 ETF - ALPS

<p>摩根大通已将启迪医疗（NYSE:INSP）的目标股价从 67.00 美元下调至 54.00 美元，维持 “中性” 评级。这一调整表明该股相较于前一交易日收盘价有 11.94% 的潜在上涨空间。其他券商也对其评级进行了调整，Piper Sandler 和 Zacks Research 下调了他们的评估。尽管发生了这些变化，仍有四位分析师将该股评级为买入，而共识评级保持为持有，目标价为 85.00 美元。启迪医疗最近公布的财报超出预期，显示出适度的收入增长</p>

<p>Inspire Medical Systems (NYSE:INSP - Get Free Report) had its target price lowered by stock analysts at JPMorgan Chase &amp; Co. from $67.00 to $54.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a &#34;neutral&#34; rating on the stock. JPMorgan Chase &amp; Co.'s target price would indicate a potential upside of 11.94% from the stock's previous close.</p>
<div class="lb-trans"><p>启迪医疗系统（NYSE:INSP - 获取免费报告）在摩根大通的分析师发布的报告中，将其目标价格从 67.00 美元下调至 54.00 美元，Benzinga 报道。该券商目前对该股票给予 “中性” 评级。摩根大通的目标价格意味着该股票相较于之前收盘价有 11.94% 的潜在上涨空间。</p>
</div><ul>
<li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li>
</ul>
<div class="lb-trans"><ul>
<li>艾利 Lilly 股票上涨：GLP-1 Zepbound 目标睡眠呼吸暂停市场</li>
</ul>
</div><p>Several other brokerages have also recently weighed in on INSP. Piper Sandler cut Inspire Medical Systems from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and decreased their price target for the company from $85.00 to $55.00 in a research note on Tuesday. Zacks Research lowered Inspire Medical Systems from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, April 14th. Royal Bank Of Canada cut their price target on Inspire Medical Systems from $56.00 to $45.00 and set a &#34;sector perform&#34; rating on the stock in a report on Tuesday. Morgan Stanley set a $60.00 target price on Inspire Medical Systems in a report on Wednesday, February 18th. Finally, Truist Financial cut their price target on shares of Inspire Medical Systems from $64.00 to $50.00 and set a &#34;hold&#34; rating on the stock in a report on Tuesday. Four analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of &#34;Hold&#34; and a consensus target price of $85.00.</p>
<div class="lb-trans"><p>其他几家券商最近也对 INSP 发表了看法。派珀·桑德勒将启迪医疗系统的评级从 “增持” 下调至 “中性”，并在周二的研究报告中将其价格目标从 85.00 美元下调至 55.00 美元。扎克斯研究在 4 月 14 日的报告中将启迪医疗系统的评级从 “强力买入” 下调至 “持有”。加拿大皇家银行在周二的报告中将启迪医疗系统的价格目标从 56.00 美元下调至 45.00 美元，并对该股票设定了 “行业表现” 评级。摩根士丹利在 2 月 18 日的报告中对启迪医疗系统设定了 60.00 美元的目标价格。最后，Truist Financial 在周二的报告中将启迪医疗系统的股票价格目标从 64.00 美元下调至 50.00 美元，并对该股票设定了 “持有” 评级。四位分析师对该股票给予了买入评级，十五位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “持有”，共识目标价格为 85.00 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on INSP</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 INSP 股票分析</strong></p>
</div><h2>Inspire Medical Systems Price Performance</h2>
<div class="lb-trans"><h2>启迪医疗系统价格表现</h2>
</div><ul>
<li>Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>启迪医疗上涨 15% 后突破，分析师称其为买入</li>
</ul>
</div><p>INSP traded down $6.60 during trading on Tuesday, hitting $48.24. The stock had a trading volume of 4,487,559 shares, compared to its average volume of 1,214,082. The company has a 50 day moving average price of $56.73 and a 200-day moving average price of $79.64. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of 9.69, a P/E/G ratio of 2.92 and a beta of 0.83. Inspire Medical Systems has a one year low of $44.41 and a one year high of $163.35.</p>
<div class="lb-trans"><p>在周二的交易中，INSP 下跌 6.60 美元，报 48.24 美元。该股票的交易量为 4,487,559 股，而其平均交易量为 1,214,082 股。该公司的 50 日移动平均价格为 56.73 美元，200 日移动平均价格为 79.64 美元。该公司的市值为 13.9 亿美元，市盈率为 9.69，市盈增长比率为 2.92，贝塔值为 0.83。启迪医疗系统的年内最低价为 44.41 美元，年内最高价为 163.35 美元。</p>
</div><p>Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The firm had revenue of $204.58 million during the quarter, compared to the consensus estimate of $200.04 million. During the same period in the prior year, the company posted $0.10 EPS. The company's revenue was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, sell-side analysts predict that Inspire Medical Systems will post 1.82 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>启迪医疗系统（NYSE:INSP - 获取免费报告）最后一次发布财报是在 5 月 4 日，周一。该公司报告每股收益为 0.10 美元，超出分析师共识预期的（0.28 美元）0.38 美元。启迪医疗系统的股本回报率为 10.96%，净利润率为 15.95%。该公司在该季度的收入为 2.0458 亿美元，而共识预期为 2.0004 亿美元。在去年同期，该公司每股收益为 0.10 美元。与去年同期相比，该公司的收入增长了 1.6%。启迪医疗系统将其 2026 财年的指导目标设定为 0.750-1.250 美元每股收益。作为一个整体，卖方分析师预测启迪医疗系统在当前财年将发布 1.82 美元的每股收益。</p>
</div><h2>Institutional Trading of Inspire Medical Systems</h2>
<div class="lb-trans"><h2>启迪医疗系统的机构交易</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否预示市场下跌？</li>
</ul>
</div><p>Hedge funds have recently made changes to their positions in the company. CWM LLC raised its stake in shares of Inspire Medical Systems by 216.1% in the fourth quarter. CWM LLC now owns 354 shares of the company's stock valued at $33,000 after buying an additional 242 shares during the period. Havemeyer Place LP bought a new stake in shares of Inspire Medical Systems in the fourth quarter valued at $39,000. V Square Quantitative Management LLC bought a new stake in shares of Inspire Medical Systems in the fourth quarter valued at $40,000. Manning &amp; Napier Advisors LLC bought a new stake in shares of Inspire Medical Systems in the third quarter valued at $32,000. Finally, Smartleaf Asset Management LLC raised its stake in shares of Inspire Medical Systems by 84.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock valued at $42,000 after buying an additional 205 shares during the period. 94.91% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>对该公司的对冲基金最近对其持仓进行了调整。CWM LLC 在第四季度将其在启迪医疗系统的股份增加了 216.1%。CWM LLC 现在拥有 354 股该公司的股票，价值 33,000 美元，此前在该期间又购买了 242 股。Havemeyer Place LP 在第四季度购买了启迪医疗系统的新股份，价值 39,000 美元。V Square Quantitative Management LLC 在第四季度购买了启迪医疗系统的新股份，价值 40,000 美元。Manning &amp; Napier Advisors LLC 在第三季度购买了启迪医疗系统的新股份，价值 32,000 美元。最后，Smartleaf Asset Management LLC 在第四季度将其在启迪医疗系统的股份增加了 84.0%。Smartleaf Asset Management LLC 现在拥有 449 股该公司的股票，价值 42,000 美元，此前在该期间又购买了 205 股。94.91% 的股票目前由机构投资者持有。</p>
</div><h2>Inspire Medical Systems News Summary</h2>
<div class="lb-trans"><h2>启迪医疗系统新闻摘要</h2>
</div><p>Here are the key news stories impacting Inspire Medical Systems this week:</p>
<div class="lb-trans"><p>以下是本周影响启迪医疗系统的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Q1 results beat estimates — Inspire reported $0.10 EPS and $204.6M in revenue, topping consensus and showing modest year‑over‑year growth; the company also released its quarter materials and slide deck. Read More.</li>
<li>Positive Sentiment: Some firms remain constructive — despite cuts to targets, Stifel and Mizuho kept buy/outperform stances (with lower price targets), indicating some analysts still see upside at lower valuations. Read More.</li>
<li>Neutral Sentiment: Full earnings call transcript and slide deck are available for detail — investors can review management’s explanations on coding, reimbursement timing and WISeR program impacts. Read More.</li>
<li>Negative Sentiment: Large FY‑2026 guidance cut — management now expects $0.75–$1.25 EPS and $825M–$875M revenue vs. street expectations near $1.99 EPS and ~$961M revenue, a materially lower outlook that drove investor concern. Read More.</li>
<li>Negative Sentiment: Reimbursement and WISeR program disruptions cited — management said coding/reimbursement timing and WISeR-related execution issues are reducing procedure volumes in 2026, the main operational reason for the weaker guidance. Read More.</li>
<li>Negative Sentiment: Multiple analyst price‑target cuts and rating shifts — several brokers trimmed targets (Truist, Wells Fargo, Baird) or moved to neutral/hold, increasing selling pressure after the guidance miss. Read More.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第一季度业绩超出预期——启迪报告每股收益 0.10 美元，收入 2.046 亿美元，超出共识并显示出适度的同比增长；该公司还发布了季度材料和幻灯片。阅读更多。</li>
<li>积极情绪：一些公司仍持建设性态度——尽管目标被下调，Stifel 和 Mizuho 仍保持买入/跑赢大盘的立场（目标价格下调），表明一些分析师仍然看到低估值的上涨空间。阅读更多。</li>
<li>中性情绪：完整的财报电话会议记录和幻灯片可供详细查看——投资者可以查看管理层对编码、报销时机和 WISeR 计划影响的解释。阅读更多。</li>
<li>消极情绪：大幅下调 2026 财年指导——管理层现在预计每股收益为 0.75–1.25 美元，收入为 8.25 亿–8.75 亿美元，而市场预期接近每股收益 1.99 美元和收入约 9.61 亿美元，这一大幅下调的前景引发了投资者的担忧。阅读更多。</li>
<li>消极情绪：提到报销和 WISeR 计划的干扰——管理层表示，编码/报销时机和与 WISeR 相关的执行问题正在减少 2026 年的手术量，这是较弱指导的主要运营原因。阅读更多。</li>
<li>消极情绪：多位分析师下调目标价格和评级——几家券商下调了目标（Truist、富国银行、贝尔德）或转为中性/持有，指导失误后增加了卖压。阅读更多。</li>
</ul>
</div><h2>Inspire Medical Systems Company Profile</h2>
<div class="lb-trans"><h2>启迪医疗系统公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.</p>
<div class="lb-trans"><p>启迪医疗系统公司是一家医疗科技公司，专注于用于治疗阻塞性睡眠呼吸暂停（OSA）的可植入神经刺激设备。该公司的旗舰产品启迪®系统，通过对舌下神经的定向刺激，在睡眠期间保持气道通畅，为对持续正压呼吸机（CPAP）设备不耐受或管理不当的患者提供了一种替代疗法。</p>
</div><p>The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.</p>
<div class="lb-trans"><p>启迪系统由一个可植入的脉冲发生器、一个监测呼吸模式的传感导线和一个激活舌下神经的刺激导线组成。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Inspire Medical Systems</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比启迪医疗系统更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=INSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inspire Medical Systems Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 到启迪医疗系统吗？</h2>
</div><p>Before you consider Inspire Medical Systems, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑启迪医疗系统之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而启迪医疗系统并不在名单上。</p>
</div><p>While Inspire Medical Systems currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然启迪医疗系统目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

JPMorgan Chase & Co. Cuts Inspire Medical Systems (NYSE:INSP) Price Target to $54.00

Market Beat

Defiance Daily Target 2X Long JPM ETF

礼来

Piper Sandler Cos

Zacks Quality International ETF

Zacks Focus Growth ETF

Zacks Small/Mid Cap ETF

Nano Labs

加拿大皇家银行

蒙特利尔银行

加拿大帝国商业银行

摩根士丹利

Truist Financial

K Wave Media

Cushman & Wakefield

SEAPEAK LLC 9% CUM RED PERP PREF UNITS SER A

Childrens Place

Harvard Ave Acquisition - Unit

Medley, Inc.

QuantumScape

Quantum-Si

Squarex Pharmaceutical Corp

曼哈顿联合软件

Hennessy Advisors

Brown Advisory US Smaller Companies PLC GBP

F&C Asset Management PLC

Arcadian Asset

Liontrust Asset Management PLC

Stifel Financial

瑞穗金融集团

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

K WAVE MEDIA LTD C/WTS 14/05/2030(TO PUR COM)

SEAPEAK LLC 8.5% CUM RED PERP PFD UNTS FXD FLT SER B

Quantum - Si - CW27

Hennessy Advisors Pref Share HNNAZ 4.875 12/31/26

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Mizuho Financial Group, Inc.

摩根大通将启迪医疗系统（NYSE:INSP）的目标价下调至 54.00 美元